
The Liver Meeting 2024
San Diego, California, US 15 November 2024 - 19 November 2024
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).

Pooled analysis ASSUREs seladelpar role in PBC
Results of the phase III ASSURE study support seladelpar – a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) – for the treatment of primary biliary cholangitis (PBC).

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.

Alcoholic drinks up risk of death in young adults with MASLD
Young adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who drink alcoholic beverages are at greater risk of mortality and of having an unhealthy liver, reports a study presented at AASLD 2024.



